Bicycle Therapeutics (NASDAQ:BCYC) Trading 8.8% Higher

Shares of Bicycle Therapeutics plc (NASDAQ:BCYCGet Rating) traded up 8.8% during mid-day trading on Thursday . The stock traded as high as $24.83 and last traded at $24.83. 1,798 shares traded hands during trading, a decline of 99% from the average session volume of 275,124 shares. The stock had previously closed at $22.82.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Piper Sandler cut their price objective on shares of Bicycle Therapeutics from $76.00 to $37.00 and set an “overweight” rating on the stock in a report on Monday, May 23rd. B. Riley lowered shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $62.00 to $33.00 in a report on Wednesday, April 13th. JMP Securities reaffirmed a “buy” rating and issued a $70.00 price target on shares of Bicycle Therapeutics in a report on Monday, June 6th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $60.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, July 6th. Finally, HC Wainwright dropped their price objective on shares of Bicycle Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Friday. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $56.92.

Bicycle Therapeutics Stock Up 3.3 %

The company has a debt-to-equity ratio of 0.09, a quick ratio of 12.14 and a current ratio of 12.14. The firm’s 50-day moving average is $18.41 and its 200 day moving average is $30.08.

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Bicycle Therapeutics had a negative return on equity of 30.84% and a negative net margin of 533.03%. Research analysts anticipate that Bicycle Therapeutics plc will post -3.51 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Candriam S.C.A. bought a new position in Bicycle Therapeutics during the 2nd quarter valued at $14,006,000. Tekla Capital Management LLC boosted its stake in Bicycle Therapeutics by 98.9% during the 2nd quarter. Tekla Capital Management LLC now owns 20,065 shares of the company’s stock valued at $337,000 after acquiring an additional 9,979 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of Bicycle Therapeutics by 76.3% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 51,027 shares of the company’s stock worth $856,000 after buying an additional 22,085 shares during the last quarter. RTW Investments LP lifted its position in shares of Bicycle Therapeutics by 46.8% in the 1st quarter. RTW Investments LP now owns 1,276,276 shares of the company’s stock worth $56,003,000 after buying an additional 407,005 shares during the last quarter. Finally, Great Point Partners LLC lifted its position in shares of Bicycle Therapeutics by 175.3% in the 1st quarter. Great Point Partners LLC now owns 550,592 shares of the company’s stock worth $24,160,000 after buying an additional 350,592 shares during the last quarter. 71.99% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

(Get Rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Featured Articles

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.